- Home
- FTRE vs ARVN Comparison
FTRE vs ARVN Comparison
Compare FTRE & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTRE
- ARVN
- Stock Information
- Founded
- FTRE 1996
- ARVN 2015
- Country
- FTRE United States
- ARVN United States
- Employees
- FTRE N/A
- ARVN N/A
- Industry
- FTRE Medical Specialities
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- FTRE Health Care
- ARVN Health Care
- Exchange
- FTRE Nasdaq
- ARVN Nasdaq
- Market Cap
- FTRE 469.0M
- ARVN 614.8M
- IPO Year
- FTRE N/A
- ARVN 2018
- Fundamental
- Price
- FTRE $5.95
- ARVN $6.81
- Analyst Decision
- FTRE Hold
- ARVN Buy
- Analyst Count
- FTRE 11
- ARVN 19
- Target Price
- FTRE $18.00
- ARVN $21.19
- AVG Volume (30 Days)
- FTRE 2.3M
- ARVN 3.3M
- Earning Date
- FTRE 05-12-2025
- ARVN 05-01-2025
- Dividend Yield
- FTRE N/A
- ARVN N/A
- EPS Growth
- FTRE N/A
- ARVN N/A
- EPS
- FTRE N/A
- ARVN N/A
- Revenue
- FTRE $2,696,400,000.00
- ARVN $426,900,000.00
- Revenue This Year
- FTRE N/A
- ARVN N/A
- Revenue Next Year
- FTRE $3.32
- ARVN N/A
- P/E Ratio
- FTRE N/A
- ARVN N/A
- Revenue Growth
- FTRE N/A
- ARVN 498.74
- 52 Week Low
- FTRE $4.77
- ARVN $5.94
- 52 Week High
- FTRE $37.24
- ARVN $37.38
- Technical
- Relative Strength Index (RSI)
- FTRE 43.28
- ARVN 36.29
- Support Level
- FTRE $5.40
- ARVN $6.23
- Resistance Level
- FTRE $6.38
- ARVN $8.00
- Average True Range (ATR)
- FTRE 0.45
- ARVN 0.58
- MACD
- FTRE 0.21
- ARVN -0.07
- Stochastic Oscillator
- FTRE 72.52
- ARVN 16.81
About FTRE Fortrea Holdings Inc.
Fortrea Holdings is a late-stage contract research organization, or CRO, that provides comprehensive Phase I through IV clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.